Enrique Fernandez, MD
Family Medicine · Miami, FLNPI 1528040086
Payments from drug & device makers
Across 181 payments — averaging $42.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Amgen$1K
- Novo Nordisk$454
- Kowa Pharmaceuticals America, Inc.$318
- Sanofi-aventis U.S. LLC$247
- GSK$199
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$4,71061%
- Food & beverage$3,06439%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $3,968 |
| Amgen(2 entities) | 6 | $1,470 |
| Novo Nordisk | 31 | $454 |
| Kowa Pharmaceuticals America, Inc. | 19 | $318 |
| Sanofi-aventis U.S. LLC | 14 | $247 |
| GSK | 11 | $199 |
| AstraZeneca | 8 | $177 |
| Lilly USA, LLC | 9 | $159 |
| E.r. Squibb & Sons, L.L.C. | 7 | $149 |
| Amarin Pharma, Inc. | 6 | $104 |
| Exact Sciences | 4 | $78 |
| Novartis | 3 | $66 |
| Lifescan, Inc. | 2 | $57 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| Abbott | 2 | $39 |
| AbbVie | 3 | $37 |
| Impel Pharmaceuticals Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Abiomed | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Pfizer | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Covidien LP | 1 | $17 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,774 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 303 | $367,259 |
| JardianceEmpagliflozin | 256 | $356,663 |
| EliquisApixaban | 280 | $291,248 |
| FarxigaDapagliflozin Propanediol | 122 | $138,253 |
| JanuviaSitagliptin Phosphate | 107 | $118,270 |
| LinzessLinaclotide | 90 | $102,121 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 76 | $98,524 |
| MounjaroTirzepatide | 72 | $96,443 |
| Tresiba Flextouch U-200Insulin Degludec | 123 | $89,274 |
| XareltoRivaroxaban | 74 | $82,610 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 63 | $78,759 |
| EntrestoSacubitril/Valsartan | 65 | $71,419 |
| JanumetSitagliptin Phos/Metformin Hcl | 60 | $68,005 |
| TrulicityDulaglutide | 50 | $62,188 |
| VascepaIcosapent Ethyl | 109 | $55,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $20 | $506,904376 claims |
| Novo NordiskOzempic, Rybelsus | $454 | $390,699316 claims |
| PfizerEliquis | $18 | $291,248280 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $177 | $174,357223 claims |
| Lilly USA, LLCMounjaro, Trulicity | $159 | $158,631122 claims |
| AbbVieLinzess, Synthroid | $37 | $114,374209 claims |
| Johnson & JohnsonXarelto, Invokana | $3,968 | $107,828104 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq | $247 | $101,41679 claims |
| NovartisEntresto | $66 | $71,41965 claims |
| AmgenProlia | $1,470 | $52,46430 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $27,73044 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $199 | $27,47450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.